Friday, June 29, 2012

Phenomenome, Polymedco Ink Pact to Commercialize Mass Spec ...

Douglas Kell has been reappointed as chief executive and deputy chair of the UK Biotechnology and Biological Sciences Research Council, the Minister for Universities and Science David Willetts said this week.

Kell has held the top post at BBSRC since 2008, and before that he was director of the Manchester Centre for Integrative Systems Biology. He also has served as director of research at the Institute of Biological Sciences at the University of Aberystwyth, and he was a founding director of Aber Instruments. His research has included a range of topics including systems biology, analytical chemistry, and biochemical and data modeling.


The Institute for Systems Biology has appointed Robert Lipshutz to be chief business officer and senior VP for strategic partnerships. Lipshutz spent nearly two decades at Affymetrix in various roles focusing on business development, licensing, diagnostics, and emerging markets, and most recently as senior VP for corporate development.


Verinata Health CEO Caren Mason has resigned but will continue to provide the company with consultative services. Mason joined Verinata in November 2010. She was previously the president and CEO of Quidel, president and CEO of MiraMedica, CEO of eMed Technologies, and general manager of GE Healthcare. The firm plans to recruit a new CEO.

Source: http://www.genomeweb.com/mdx/phenomenome-polymedco-ink-pact-commercialize-mass-spec-based-colorectal-cancer-t

giants super bowl 2012 half time show halftime show 2012 kelly clarkson super bowl 2012 giants ny giants ok go

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.